Changeflow GovPing Healthcare & Life Sciences FDA Acknowledgment Letter to Life to the Full, LLC
Routine Notice Added Final

FDA Acknowledgment Letter to Life to the Full, LLC

Email

Summary

The Food and Drug Administration (FDA) has issued an acknowledgment letter to Life to the Full, LLC. This letter confirms receipt of a submission from the company. The FDA's Center for Devices and Radiological Health (CDRH) is listed as an author.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is an acknowledgment letter from the FDA's Division of Management Services (DMB) to Life to the Full, LLC, confirming receipt of a submission. The letter, authored by CDRH, serves as official notification that the FDA has received the company's filing. No substantive regulatory changes or new obligations are introduced by this acknowledgment.

Compliance officers should note this as a routine administrative communication. No immediate actions are required based on this acknowledgment letter. It confirms a submission has been received by the agency, but does not indicate approval or provide guidance on the substance of the submission itself. Further regulatory actions or communications from the FDA regarding this submission would be communicated separately.

Archived snapshot

Mar 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Acknowledgment Letter from FDA DMB to Life to the Full, LLC

More Information
- Author(s) CDRH
Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2025-V-7065-0002
Docket
FDA-2025-V-7065

Who this affects

Applies to
Drug manufacturers Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Regulatory Submissions
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11
Topics
Medical Devices

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!